Back to top

Halozyme Therapeutics, Inc. (HALO)

(Delayed Data from NSDQ)

$40.91 USD


+0.50 (1.24%)

Updated Mar 5, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
5Strong Sell1.87%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (192 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

Kinjel Shah headshot

Drug/Biotech Stock Q4 Earnings on Feb 23: JAZZ, ARNA & More

Let us take a look at five small biotech companies, JAZZ, ARNA, HALO, EPZM, ESPR, which are gearing up for their earnings release.

UnitedHealth (UNH) Q4 Earnings Top Estimates, Revenues up Y/Y

UnitedHealth's (UNH) fourth-quarter results benefit from higher revenues and return of healthcare utilization to normalcy level, partly offset by higher costs.

Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis

J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA

Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.

Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment

Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.

AbbVie (ABBV) Inks Deal to Acquire Medical Device Company

AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

Editas (EDIT) Gets FDA Nod to Begin Safety Study on EDIT-301

The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.

bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity

bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.

Horizon (HZNP) Provides Preliminary 2020 Financial Results

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance

Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.

Sarepta (SRPT) Looks Good: Stock Adds 9.1% in Session

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

Infrastructure and Energy Alternatives, Carrols Restaurant, Moderna, Blueprint Medicines and Halozyme Therapeutics highlighted as Zacks Bull and Bear of the Day

Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study

Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio in 2021

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%

Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.